New trends in guided nanotherapies for digestive cancers: A systematic review

Journal of Controlled Release

Volumn 209, Issue , 2015, Pages 288-307

  Fernandes, Elisabete ^a,b,c   Ferreira, José Alexandre ^a,d   Andreia, Peixoto ^a   Luís, Lima ^a,e   Barroso, Sérgio ^f   Sarmento, Bruno ^b,c,g   Santos, Lúcio Lara ^a,h  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

^d UNIVERSITY OF AVEIRO   (Portugal)

^e POLYTECHNIC INSTITUTE OF PORTO   (Portugal)

^f Hospital Distrital de Evora   (Portugal)

^g INSTITUTO DE INVESTIGAÇÃO E FORMAÇÃO AVANÇADA EM CIÊNCIAS E TECNOLOGIAS DA SAÚDE   (Portugal)

^h UNIVERSIDADE FERNANDO PESSOA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; BIOCOMPATIBILITY; CHEMOTHERAPY; CLONE CELLS; CLONING; CYTOLOGY; DISEASES; DRUG DOSAGE; DRUG INTERACTIONS; ENZYME INHIBITION; INTELLIGENT AGENTS; LIGANDS; LIPOSOMES; MONOCLONAL ANTIBODIES; NANOPARTICLES; POLYMERS; PROTEINS; STEM CELLS; TUMORS;

ADJUVANT CHEMOTHERAPY; CHEMOTHERAPEUTIC AGENTS; CURRENT TREATMENTS; EFFECTIVE SOLUTION; NANO-ENCAPSULATION; NANOPARTICLE SURFACE; NANOPHARMACEUTICALS; SYSTEMIC TOXICITIES;

DIAGNOSIS;

DRUG; GLYCAN; IMMUNOLIPOSOME; MONOCLONAL ANTIBODY; NANOPARTICLE; OXALIPLATIN; TRANSFERRIN; ANTINEOPLASTIC AGENT;

CANCER CELL; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER THERAPY; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TREND STUDY; TUMOR RECURRENCE; ANIMAL; DIGESTIVE SYSTEM NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; DIGESTIVE SYSTEM NEOPLASMS; HUMANS; NANOPARTICLES;

EID: 84929376547     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.05.003     Document Type: Review

References (219)

1. F. Ferlay, J. Soerjomataram, I. Ervik, M. Dikshit, R. Eser, S. Mathers, C. Rebelo, M. Parkin, D.M. Forman, and D. Bray GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet] 2012 Int. Agency Res. Cancer Lyon, Fr. 2012 2015 (2013)
2. E. Karakas, C. Oetzmann von Sochaczewski, T. Haist, M. Pauthner, and D. Lorenz Limitations of surgery for cancer of the upper gastrointestinal tract Chirurg 85 2014 186 191 10.1007/s00104-013-2598-5
3. A.S. Thakor, and S.S. Gambhir Nanooncology: the future of cancer diagnosis and therapy CA Cancer J. Clin. 63 2013 395 418 10.1002/caac.21199
4. X. Cheng, and H. Chen Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives Onco Targets Ther. 7 2014 1689 1704 10.2147/OTT.S66502
5. P. Ramos, and M. Bentires-Alj Mechanism-based cancer therapy: resistance to therapy, therapy for resistance Oncogene 2014 10.1038/onc.2014.314
6. R.A. Burrell, and C. Swanton Tumour heterogeneity and the evolution of polyclonal drug resistance Mol. Oncol. 8 2014 1095 1111 10.1016/j.molonc.2014.06.005
7. M. Rebucci, and C. Michiels Molecular aspects of cancer cell resistance to chemotherapy Biochem. Pharmacol. 85 2013 1219 1226 10.1016/j.bcp.2013.02.017
8. N. Ahmed, K. Abubaker, J. Findlay, and M. Quinn Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer Curr. Cancer Drug Targets 10 2010 268 278 (http://www.ncbi.nlm.nih.gov/pubmed/20370691 (accessed January 15, 2015))
9. C.Q. Xia, and P.G. Smith Drug efflux transporters and multidrug resistance in acute leukemia: therapeutic impact and novel approaches to mediation Mol. Pharmacol. 82 2012 1008 1021 10.1124/mol.112.079129
10. H. Guo, Q. Lai, W. Wang, Y. Wu, C. Zhang, and Y. Liu Functional alginate nanoparticles for efficient intracellular release of doxorubicin and hepatoma carcinoma cell targeting therapy Int. J. Pharm. 451 2013 1 11 10.1016/j.ijpharm.2013.04.025
11. R. Sinha, G.J. Kim, S. Nie, and D.M. Shin Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery Mol. Cancer Ther. 5 2006 1909 1917 10.1158/1535-7163.MCT-06-0141
12. T. Minko, L. Rodriguez-Rodriguez, and V. Pozharov Nanotechnology approaches for personalized treatment of multidrug resistant cancers Adv. Drug Deliv. Rev. 65 2013 1880 1895 10.1016/j.addr.2013.09.017
13. M. Berretta, F. Di Benedetto, R. Di Francia, E. Lo Menzo, S. Palmeri, and P. De Paoli Colorectal cancer in elderly patients: from best supportive care to cure Anti Cancer Agents Med. Chem. 13 2013 1332 1343 (http://www.ncbi.nlm.nih.gov/pubmed/24102277 (accessed January 15, 2015))
14. A. Gómez Portilla, C. Martínez de Lecea, I. Cendoya, I. Olabarría, E. Martín, and L. Magrach Prevalence and treatment of oncologic disease in the elderly - an impeding challenge Rev. Esp. Enferm. Dig. 100 2008 706 715 (http://www.ncbi.nlm.nih.gov/pubmed/19159175, accessed January 16, 2015).
15. X. Xu, W. Ho, X. Zhang, N. Bertrand, and O. Farokhzad Cancer nanomedicine: from targeted delivery to combination therapy Trends Mol. Med. 21 2015 223 232 10.1016/j.molmed.2015.01.001
16. N. Ahmed, H. Fessi, and A. Elaissari Theranostic applications of nanoparticles in cancer Drug Discov. Today 17 2012 928 934 10.1016/j.drudis.2012.03.010
17. L. Zhang, F. Gu, and J. Chan Nanoparticles in medicine: therapeutic applications and developments Clin. Pharmacol. Ther. 83 2007 761 769 10.1038/sj.clp
18. J.D. Byrne, T. Betancourt, and L. Brannon-Peppas Active targeting schemes for nanoparticle systems in cancer therapeutics Adv. Drug Deliv. Rev. 60 2008 1615 1626 10.1016/j.addr.2008.08.005
19. T. Stylianopoulos, C. Wong, M.G. Bawendi, R.K. Jain, and D. Fukumura Multistage nanoparticles for improved delivery into tumor tissue Methods Enzymol. 508 2012 109 130 10.1016/B978-0-12-391860-4.00006-9
20. P. Sapra, and T.M. Allen Ligand-targeted liposomal anticancer drugs Prog. Lipid Res. 42 2003 439 462 10.1016/S0163-7827(03)00032-8
21. A.K. Iyer, G. Khaled, J. Fang, and H. Maeda Exploiting the enhanced permeability and retention effect for tumor targeting Drug Discov. Today 11 2006 812 818 10.1016/j.drudis.2006.07.005
22. T.M. Allen Ligand-targeted therapeutics in anticancer therapy Nat. Rev. Cancer 2 2002 750 763 10.1038/nrc903
23. C. Brignole, F. Pastorino, D. Marimpietri, G. Pagnan, A. Pistorio, and T.M. Allen Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs J. Natl. Cancer Inst. 96 2004 1171 1180 10.1093/jnci/djh221
24. F. Danhier, E. Ansorena, J.M. Silva, R. Coco, A. Le Breton, and V. Préat PLGA-based nanoparticles: an overview of biomedical applications J. Control. Release 161 2012 505 522 10.1016/j.jconrel.2012.01.043
25. N. Malik, E. Evagorou, and R. Duncan Dendrimer-platinate: a novel approach to cancer chemotherapy Anticancer Drugs 10 1999 767 776 10.1097/00001813-199909000-00010
26. J. Yue, S. Liu, R. Wang, X. Hu, Z. Xie, and Y. Huang Transferrin-conjugated micelles: enhanced accumulation and antitumor effect for transferrin-receptor-overexpressing cancer models Mol. Pharm. 9 2012 1919 1931 10.1021/mp300213g
27. A. Bhirde, V. Patel, J. Gavard, and G. Zhang Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery ACS Nano 3 2009 307 316 10.1021/nn800551s.Targeted
28. S. Sundarraj, R. Thangam, M.V. Sujitha, K. Vimala, and S. Kannan Ligand-conjugated mesoporous silica nanorattles based on enzyme targeted prodrug delivery system for effective lung cancer therapy Toxicol. Appl. Pharmacol. 275 2014 232 243 10.1016/j.taap.2014.01.012
29. S. Shanehsazzadeh, C. Gruettner, A. Lahooti, M. Mahmoudi, B.J. Allen, and M. Ghavami Monoclonal antibody conjugated magnetic nanoparticles could target MUC-1-positive cells in vitro but not in vivo Contrast Media Mol. Imaging 2014 10.1002/cmmi.1627
30. T. Van Dyke, and T. Jacks Cancer modeling in the modern era Cell 108 2002 135 144 10.1016/S0092-8674(02)00621-9
31. M.R. Grever, S.A. Schepartz, and B.A. Chabner The National Cancer Institute: cancer drug discovery and development program Semin. Oncol. 19 1992 622 638 (http://www.ncbi.nlm.nih.gov/pubmed/1462164 (accessed November 20, 2014))
32. L. Treuel, X. Jiang, and G.U. Nienhaus New views on cellular uptake and trafficking of manufactured nanoparticles J. R. Soc. Interface 10 2013 20120939 10.1098/rsif.2012.0939
33. D.L. Stirland, J.W. Nichols, S. Miura, and Y.H. Bae Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice J. Control. Release 172 2013 1045 1064 10.1016/j.jconrel.2013.09.026
34. J.M. Rabanel, V. Aoun, I. Elkin, M. Mokhtar, and P. Hildgen Drug-loaded nanocarriers: passive targeting and crossing of biological barriers Curr. Med. Chem. 19 2012 3070 3102 10.2174/092986712800784702
35. S.K. Sriraman, B. Aryasomayajula, and V.P. Torchilin Barriers to drug delivery in solid tumors Tissue Barriers 2 2014 e29528 10.4161/tisb.29528
36. F. Marcucci, and F. Lefoulon Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress Drug Discov. Today 9 2004 219 228 10.1016/S1359-6446(03)02988-X
37. T. Asai, K. Shimizu, M. Kondo, K. Kuromi, K. Watanabe, and K. Ogino Anti-neovascular therapy by liposomal DPP-CNDAC targeted to angiogenic vessels FEBS Lett. 520 2002 167 170 (http://www.ncbi.nlm.nih.gov/pubmed/12044891)
38. T. Lammers, F. Kiessling, W.E. Hennink, and G. Storm Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress J. Control. Release 161 2012 175 187 10.1016/j.jconrel.2011.09.063
39. N. Bertrand, J. Wu, X. Xu, N. Kamaly, and O.C. Farokhzad Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology Adv. Drug Deliv. Rev. 2013 1 24 10.1016/j.addr.2013.11.009
40. M. Sugano, N.K. Egilmez, S.J. Yokota, F. Chen, J. Harding, and S.K. Huang Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice Clin. Cancer Res. 60 2000 6942 6949
41. Y.-Z. Du, L.-L. Cai, P. Liu, J. You, H. Yuan, and F.-Q. Hu Tumor cells-specific targeting delivery achieved by A54 peptide functionalized polymeric micelles Biomaterials 33 2012 8858 8867 10.1016/j.biomaterials.2012.08.043
42. Y. Cao, D. Chen, P. Zhao, L. Liu, X. Huang, and C. Qi Intracellular delivery of mitomycin C with targeted polysaccharide conjugates against multidrug resistance Ann. Biomed. Eng. 39 2011 2456 2465 10.1007/s10439-011-0333-2
43. O.C. Farokhzad, S. Jon, A. Khademhosseini, T.T. Tran, D.A. Lavan, and R. Langer Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells Cancer Res. 2004 7668 7672
44. R. Dinarvand, P. Cesar de Morais, and A. D'Emanuele Nanoparticles for targeted delivery of active agents against tumor cells J. Drug Deliv. 2012 2012 528123 10.1155/2012/528123
45. J.W. Park, K. Hong, D.B. Kirpotin, G. Colbern, R. Shalaby, and J. Baselga Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery Clin. Cancer Res. 8 2002 1172 1181
46. G.A. Niehans, T.P. Singleton, D. Dykoski, and D.T. Kiang Stability of HER-2/neu expression over time and at multiple metastatic sites J. Natl. Cancer Inst. 85 1993 1230 1235 (http://www.ncbi.nlm.nih.gov/pubmed/8101229 (accessed January 16, 2015))
47. S. Bamrungsap, Z. Zhao, T. Chen, L. Wang, C. Li, and T. Fu Nanotechnology in therapeutics: a focus on nanoparticles as a drug delivery system Nanomedicine (London) 7 2012 1253 1271 10.2217/nnm.12.87
48. J.F. Kukowska-Latallo, K.A. Candido, Z. Cao, S.S. Nigavekar, I.J. Majoros, and T.P. Thomas Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer Cancer Res. 65 2005 5317 5324 10.1158/0008-5472.CAN-04-3921
49. S.K. Sahoo, W. Ma, and V. Labhasetwar Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer Int. J. Cancer 112 2004 335 340 10.1002/ijc.20405
50. A. Liberati, D.G. Altman, J. Tetzlaff, C. Mulrow, P.C. Gøtzsche, and J.P.A. Ioannidis The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration PLoS Med. 6 2009 e1000100 10.1371/journal.pmed.1000100
51. Y. Cao, Y. Gu, H. Ma, J. Bai, L. Liu, and P. Zhao Self-assembled nanoparticle drug delivery systems from galactosylated polysaccharide-doxorubicin conjugate loaded doxorubicin Int. J. Biol. Macromol. 46 2010 245 249 10.1016/j.ijbiomac.2009.11.008
52. L. Shi, C. Tang, and C. Yin Glycyrrhizin-modified O-carboxymethyl chitosan nanoparticles as drug vehicles targeting hepatocellular carcinoma Biomaterials 33 2012 7594 7604 10.1016/j.biomaterials.2012.06.072
53. M. Cheng, Z. Liu, T. Wan, B. He, B. Zha, and J. Han Preliminary pharmacology of galactosylated chitosan/5-fluorouracil nanoparticles and its inhibition of hepatocellular carcinoma in mice Cancer Biol. Ther. 13 2012 1407 1416 10.4161/cbt.22001
54. Y.-M. Li, S.-C. Xu, J. Li, K.-Q. Han, H.-F. Pi, and L. Zheng Epithelial-mesenchymal transition markers expressed in circulating tumor cells in hepatocellular carcinoma patients with different stages of disease Cell Death Dis. 4 2013 e831 10.1038/cddis.2013.347
55. W. Xu, L. Cao, L. Chen, J. Li, X.-F. Zhang, and H.-H. Qian Isolation of circulating tumor cells in patients with hepatocellular carcinoma using a novel cell separation strategy Clin. Cancer Res. 17 2011 3783 3793 10.1158/1078-0432.CCR-10-0498
56. L.W. Seymour, D.R. Ferry, D. Anderson, S. Hesslewood, P.J. Julyan, and R. Poyner Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin J. Clin. Oncol. 20 2002 1668 1676 (http://www.ncbi.nlm.nih.gov/pubmed/11896118)
57. M.V. Pimm, A.C. Perkinsf, J.I.M. Strohalm, K. Ulbiuch, and R. Duncan Gamma scintigraphy of a 1231-labelled N-(2-hydroxypropyl) methacrylamide copolymer-doxorubicin conjugate containing galactosamine following intravenous administration to nude mice bearing hepatic human colon carcinoma J. Drug Target. 3 1996 385 390
58. D. Trerè, L. Fiume, L.B. De Giorgi, G. Di Stefano, M. Migaldi, and M. Derenzini The asialoglycoprotein receptor in human hepatocellular carcinomas: its expression on proliferating cells Br. J. Cancer 81 1999 404 408 10.1038/sj.bjc.6690708
59. T.M. Allen, and P.R. Cullis Drug delivery systems: entering the mainstream Science 303 2004 1818 1822 10.1126/science.1095833
60. J.H. Ryu, H. Koo, I.-C. Sun, S.H. Yuk, K. Choi, and K. Kim Tumor-targeting multi-functional nanoparticles for theragnosis: new paradigm for cancer therapy Adv. Drug Deliv. Rev. 64 2012 1447 1458 10.1016/j.addr.2012.06.012
61. D.L. Iu, H.U. Haiyang, J.Z. Hang, X.Z. Hao, X.T. Ang, and D.C. Hen Drug pH-sensitive release in vitro and targeting ability of polyamidoamine dendrimer complexes for tumor cells Chem. Pharm. Bull. 59 2011 63 71
62. X. Zhou, M. Zhang, B. Yung, H. Li, C. Zhou, and L.J. Lee Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma Int. J. Nanomedicine 7 2012 5465 5474 10.2147/IJN.S33965
63. M. Cheng, J. Han, Q. Li, B. He, B. Zha, and J. Wu Synthesis of galactosylated chitosan/5-fluorouracil nanoparticles and its characteristics, in vitro and in vivo release studies J. Biomed. Mater. Res. B Appl. Biomater. 100 2012 2035 2043 10.1002/jbm.b.32767
64. T. Jiang, Z. Zhang, Y. Zhang, H. Lv, J. Zhou, and C. Li Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery Biomaterials 33 2012 9246 9258 10.1016/j.biomaterials.2012.09.027
65. M.-R. Cheng, Q. Li, T. Wan, B. He, J. Han, and H.-X. Chen Galactosylated chitosan/5-fluorouracil nanoparticles inhibit mouse hepatic cancer growth and its side effects World J. Gastroenterol. 18 2012 6076 6087 10.3748/wjg.v18.i42.6076
66. J.-E. Chang, W.-S. Shim, S.-G. Yang, E.-Y. Kwak, S. Chong, and D.-D. Kim Liver cancer targeting of Doxorubicin with reduced distribution to the heart using hematoporphyrin-modified albumin nanoparticles in rats Pharm. Res. 29 2012 795 805 10.1007/s11095-011-0603-6
67. M. Yamamoto, K. Ichinose, N. Ishii, T. Khoji, K. Akiyoshi, and N. Moriguchi Utility of liposomes coated with polysaccharide bearing 1-amino-lactose as targeting chemotherapy for AH66 hepatoma cells Oncol. Rep. 7 2000 107 111 (http://www.ncbi.nlm.nih.gov/pubmed/10601602 (accessed July 5, 2014))
68. C. Cheng, B. He, T. Wan, W. Zhu, J. Han, and B. Zha 5-Fluorouracil nanoparticles inhibit hepatocellular carcinoma via activation of the p53 pathway in the orthotopic transplant mouse model PLoS One 7 2012 e47115 10.1371/journal.pone.0047115
69. R. Duncan, L.C. Seymour, L. Scarlett, J.B. Lloyd, P. Rejmanová, and J. Kopecek Fate of N-(2-hydroxypropyl)methacrylamide copolymers with pendent galactosamine residues after intravenous administration to rats Biochim. Biophys. Acta 880 1986 62 71 (http://www.ncbi.nlm.nih.gov/pubmed/3942780 (accessed January 19, 2015))
70. R.P. Evarts, E. Marsden, P. Hanna, P.J. Wirth, and S.S. Thorgeirsson Isolation of preneoplastic rat liver cells by centrifugal elutriation and binding to asialofetuin Cancer Res. 44 1984 5718 5724 (http://www.ncbi.nlm.nih.gov/pubmed/6209000 (accessed January 29, 2015))
71. G. Ashwell, and A.G. Morell The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins Adv. Enzymol. Relat. Areas Mol. Biol. 41 1974 99 128 (http://www.ncbi.nlm.nih.gov/pubmed/4609051 (accessed January 29, 2015))
72. P.A. Vasey, S.B. Kaye, R. Morrison, C. Twelves, P. Wilson, and R. Duncan Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee Clin. Cancer Res. 5 1999 83 94 (http://www.ncbi.nlm.nih.gov/pubmed/9918206, accessed January 28, 2015)
73. F. Danhier, B. Vroman, N. Lecouturier, N. Crokart, V. Pourcelle, and H. Freichels Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel J. Control. Release 140 2009 166 173 10.1016/j.jconrel.2009.08.011
74. F. Danhier, B. Ucakar, N. Magotteaux, M.E. Brewster, and V. Préat Active and passive tumor targeting of a novel poorly soluble cyclin dependent kinase inhibitor, JNJ-7706621 Int. J. Pharm. 392 2010 20 28 10.1016/j.ijpharm.2010.03.018
75. Y. Yang, J.-S. Jiang, B. Du, Z.-F. Gan, M. Qian, and P. Zhang Preparation and properties of a novel drug delivery system with both magnetic and biomolecular targeting J. Mater. Sci. Mater. Med. 20 2009 301 307 10.1007/s10856-008-3577-0
76. L. Han, R. Huang, and S. Liu Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors Mol. Pharm. 46 2010 6387 6392 10.3109/10611861003733953. (14)
77. J.H. Lee, J.A. Engler, J.F. Collawn, and B.A. Moore Receptor mediated uptake of peptides that bind the human transferrin receptor Eur. J. Biochem. 268 2001 2004 2012 (http://www.ncbi.nlm.nih.gov/pubmed/11277922 (accessed January 19, 2015))
78. S. Oh, B.J. Kim, N.P. Singh, H. Lai, and T. Sasaki Synthesis and anti-cancer activity of covalent conjugates of artemisinin and a transferrin-receptor targeting peptide Cancer Lett. 274 2009 33 39 10.1016/j.canlet.2008.08.031
79. K. Sakurai, T. Sohda, S.-I. Ueda, T. Tanaka, G. Hirano, and K. Yokoyama Immunohistochemical demonstration of transferrin receptor 1 and 2 in human hepatocellular carcinoma tissue Hepatogastroenterology 61 2014 426 430 (http://www.ncbi.nlm.nih.gov/pubmed/24901155 (accessed January 20, 2015))
80. R. SCIOT, A.C. PATERSON, P. EYKEN, F. CALLEA, M.C. KEW, and V.J. DESMET Transferrin receptor expression in human hepatocellular carcinoma: an immunohistochemical study of 34 cases Histopathology 12 1988 53 63 10.1111/j.1365-2559.1988.tb01916.x
81. C.E. Herbison, K. Thorstensen, A.C.G. Chua, R.M. Graham, P. Leedman, and J.K. Olynyk The role of transferrin receptor 1 and 2 in transferrin-bound iron uptake in human hepatoma cells Am. J. Physiol. Cell Physiol. 297 2009 C1567 C1575 10.1152/ajpcell.00649.2008
82. S. Deaglio, A. Capobianco, A. Calì, F. Bellora, F. Alberti, and L. Righi Structural, functional, and tissue distribution analysis of human transferrin receptor-2 by murine monoclonal antibodies and a polyclonal antiserum Blood 100 2002 3782 3789 10.1182/blood-2002-01-0076
83. H.Y. Dong, S. Wilkes, and H. Yang CD71 is selectively and ubiquitously expressed at high levels in erythroid precursors of all maturation stages: a comparative immunochemical study with glycophorin A and hemoglobin A Am. J. Surg. Pathol. 35 2011 723 732 10.1097/PAS.0b013e31821247a8
84. B. Du, H. Han, Z. Wang, L. Kuang, L. Wang, and L. Yu Targeted drug delivery to hepatocarcinoma in vivo by phage-displayed specific binding peptide Mol. Cancer Res. 8 2010 135 144 10.1158/1541-7786.MCR-09-0339
85. E.A. Murphy, B.K. Majeti, L.A. Barnes, M. Makale, S.M. Weis, and K. Lutu-Fuga Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis Proc. Natl. Acad. Sci. U. S. A. 105 2008 9343 9348 10.1073/pnas.0803728105
86. E. Garanger, D. Boturyn, J.-L. Coll, M.-C. Favrot, and P. Dumy Multivalent RGD synthetic peptides as potent alphaVbeta3 integrin ligands Org. Biomol. Chem. 4 2006 1958 1965 10.1039/b517706e
87. P.C. Brooks, R.A. Clark, and D.A. Cheresh Requirement of vascular integrin alpha v beta 3 for angiogenesis Science 264 1994 569 571 (http://www.ncbi.nlm.nih.gov/pubmed/7512751 (accessed January 14, 2015))
88. J.S. Desgrosellier, and D.A. Cheresh Integrins in cancer: biological implications and therapeutic opportunities Nat. Rev. Cancer 10 2010 9 22 10.1038/nrc2748
89. R.O. Hynes A reevaluation of integrins as regulators of angiogenesis Nat. Med. 8 2002 918 921 10.1038/nm0902-918
90. W. Arap Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model Science 279 80- 1998 377 380 10.1126/science.279.5349.377
91. Y. Yuan, W. Wang, B. Wang, H. Zhu, B. Zhang, and M. Feng Delivery of hydrophilic drug doxorubicin hydrochloride-targeted liver using apoAI as carrier J. Drug Target. 21 2013 367 374 10.3109/1061186X.2012.757769
92. L. Wang, W. Su, Z. Liu, M. Zhou, S. Chen, and Y. Chen CD44 antibody-targeted liposomal nanoparticles for molecular imaging and therapy of hepatocellular carcinoma Biomaterials 33 2012 5107 5114 10.1016/j.biomaterials.2012.03.067
93. P. Roth, C. Hammer, A.-C. Piguet, M. Ledermann, J.-F. Dufour, and E. Waelti Effects on hepatocellular carcinoma of doxorubicin-loaded immunoliposomes designed to target the VEGFR-2 J. Drug Target. 15 2007 623 631 10.1080/10611860701502723
94. C. Jin, N. Qian, W. Zhao, W. Yang, L. Bai, and H. Wu Improved therapeutic effect of DOX-PLGA-PEG micelles decorated with bivalent fragment HAb18 F(ab′)(2) for hepatocellular carcinoma Biomacromolecules 11 2010 2422 2431 10.1021/bm1005992
95. S. Lingala, Y.-Y. Cui, X. Chen, B.H. Ruebner, X.-F. Qian, and M.A. Zern Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinoma Exp. Mol. Pathol. 89 2010 27 35 10.1016/j.yexmp.2010.05.005
96. N. Hashimoto, R. Tsunedomi, K. Yoshimura, Y. Watanabe, S. Hazama, and M. Oka Cancer stem-like sphere cells induced from de-differentiated hepatocellular carcinoma-derived cell lines possess the resistance to anti-cancer drugs BMC Cancer 14 2014 722 10.1186/1471-2407-14-722
97. J. Fernando, A. Malfettone, E.B. Cepeda, R. Vilarrasa-Blasi, E. Bertran, and G. Raimondi A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells Int. J. Cancer 136 2015 E161 E172 10.1002/ijc.29097
98. P. Kunkel, U. Ulbricht, P. Bohlen, M.A. Brockmann, R. Fillbrandt, and D. Stavrou Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2 Cancer Res. 61 2001 6624 6628 (http://www.ncbi.nlm.nih.gov/pubmed/11559524 (accessed January 20, 2015))
99. H. Watanabe, A.J. Mamelak, B. Wang, B.G. Howell, I. Freed, and C. Esche Anti-vascular endothelial growth factor receptor-2 (Flk-1/KDR) antibody suppresses contact hypersensitivity Exp. Dermatol. 13 2004 671 681 10.1111/j.0906-6705.2004.00240.x
100. Y.-K. Kim, A. Minai-Tehrani, J.-H. Lee, C.-S. Cho, M.-H. Cho, and H.-L. Jiang Therapeutic efficiency of folated poly(ethylene glycol)-chitosan-graft-polyethylenimine-Pdcd4 complexes in H-ras12V mice with liver cancer Int. J. Nanomedicine 8 2013 1489 1498 10.2147/IJN.S42949
101. J.H. Maeng, D.-H. Lee, K.H. Jung, Y.-H. Bae, I.-S. Park, and S. Jeong Multifunctional doxorubicin loaded superparamagnetic iron oxide nanoparticles for chemotherapy and magnetic resonance imaging in liver cancer Biomaterials 31 2010 4995 5006 10.1016/j.biomaterials.2010.02.068
102. Y. Satomi, H. Nishino, and S. Shibata Glycyrrhetinic acid and related compounds induce G1 arrest and apoptosis in human hepatocellular carcinoma HepG2 Anticancer Res. 25 2005 4043 4047 (http://www.ncbi.nlm.nih.gov/pubmed/16309197 (accessed January 20, 2015))
103. H. Hibasami, H. Iwase, K. Yoshioka, and H. Takahashi Glycyrrhetic acid (a metabolic substance and aglycon of glycyrrhizin) induces apoptosis in human hepatoma, promyelotic leukemia and stomach cancer cells Int. J. Mol. Med. 17 2006 215 219 (http://www.ncbi.nlm.nih.gov/pubmed/16391818 (accessed January 20, 2015))
104. Q. Tian, X.-H. Wang, W. Wang, C.-N. Zhang, P. Wang, and Z. Yuan Self-assembly and liver targeting of sulfated chitosan nanoparticles functionalized with glycyrrhetinic acid Nanomedicine 8 2012 870 879 10.1016/j.nano.2011.11.002
105. W. Huang, W. Wang, P. Wang, C.-N. Zhang, Q. Tian, and Y. Zhang Glycyrrhetinic acid-functionalized degradable micelles as liver-targeted drug carrier J. Mater. Sci. Mater. Med. 22 2011 853 863 10.1007/s10856-011-4262-2
106. Q. Tian, C.-N. Zhang, X.-H. Wang, W. Wang, W. Huang, and R.-T. Cha Glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles for liver-targeted delivery Biomaterials 31 2010 4748 4756 10.1016/j.biomaterials.2010.02.042
107. J. Li, H. Xu, X. Ke, and J. Tian The anti-tumor performance of docetaxel liposomes surface-modified with glycyrrhetinic acid J. Drug Target. 20 2012 467 473 10.3109/1061186X.2012.685475
108. M. Negishi, A. Irie, N. Nagata, and A. Ichikawa Specific binding of glycyrrhetinic acid to the rat liver membrane Biochim. Biophys. Acta 1066 1991 77 82 (http://www.ncbi.nlm.nih.gov/pubmed/2065071 (accessed January 20, 2015))
109. J. Wolfram, M. Zhu, Y. Yang, J. Shen, E. Gentile, and D. Paolino Safety of nanoparticles in medicine Curr. Drug Targets 2014 (http://www.ncbi.nlm.nih.gov/pubmed/25090989, accessed January 29, 2015) (ahead of print)
110. T. Chandy, G.S. Das, and G.H. Rao 5-Fluorouracil-loaded chitosan coated polylactic acid microspheres as biodegradable drug carriers for cerebral tumours J. Microencapsul. 17 2000 625 638 10.1080/026520400417676
111. L. Zhu, J. Ma, N. Jia, Y. Zhao, and H. Shen Chitosan-coated magnetic nanoparticles as carriers of 5-fluorouracil: preparation, characterization and cytotoxicity studies Colloids Surf. B: Biointerfaces 68 2009 1 6 10.1016/j.colsurfb.2008.07.020
112. J.-A. Guu, G.-H. Hsiue, and T.-M. Juang Synthesis and biological properties of antitumor-active conjugates of ADR with dextran J. Biomater. Sci. Polym. Ed. 13 2002 1135 1151 (http://www.ncbi.nlm.nih.gov/pubmed/12484489 (accessed July 5, 2014))
113. D.-K. Chang, C.-Y. Chiu, S.-Y. Kuo, W.-C. Lin, A. Lo, and Y.-P. Wang Antiangiogenic targeting liposomes increase therapeutic efficacy for solid tumors J. Biol. Chem. 284 2009 12905 12916 10.1074/jbc.M900280200
114. R.K. Jain, N. Safabakhsh, A. Sckell, Y. Chen, P. Jiang, and L. Benjamin Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor Proc. Natl. Acad. Sci. U. S. A. 95 1998 10820 10825 (http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=27979&tool=pmcentrez&rendertype=abstract, accessed November 28, 2014).
115. R.M. Schiffelers, G.A. Koning, T.L.M. ten Hagen, M.H.A.M. Fens, A.J. Schraa, and A.P.C.A. Janssen Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin J. Control. Release 91 2003 115 122 (http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3885379&tool=pmcentrez&rendertype=abstract)
116. A. Wicki, C. Rochlitz, A. Orleth, R. Ritschard, I. Albrecht, and R. Herrmann Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth Clin. Cancer Res. 18 2012 454 464 10.1158/1078-0432.CCR-11-1102
117. K. Shimizu, T. Asai, C. Fuse, Y. Sadzuka, T. Sonobe, and K. Ogino Applicability of anti-neovascular therapy to drug-resistant tumor: suppression of drug-resistant P388 tumor growth with neovessel-targeted liposomal adriamycin Int. J. Pharm. 296 2005 133 141 10.1016/j.ijpharm.2005.02.030
118. N. Oku, T. Asai, K. Watanabe, K. Kuromi, M. Nagatsuka, and K. Kurohane Anti-neovascular therapy using novel peptides homing to angiogenic vessels Oncogene 21 2002 2662 2669 10.1038/sj.onc.1205347
119. T. Asai, S. Miyazawa, N. Maeda, K. Hatanaka, Y. Katanasaka, and K. Shimizu Antineovascular therapy with angiogenic vessel-targeted polyethyleneglycol-shielded liposomal DPP-CNDAC Cancer Sci. 99 2008 1029 1033 10.1111/j.1349-7006.2008.00758.x
120. N. Maeda, Y. Takeuchi, M. Takada, Y. Sadzuka, Y. Namba, and N. Oku Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome J. Control. Release 100 2004 41 52 10.1016/j.jconrel.2004.07.033
121. A. Matsuda, Y. Nakajima, A. Azuma, M. Tanaka, and T. Sasaki Nucleosides and nucleotides. 100. 2′-C-cyano-2′-deoxy-1-beta-D-arabinofuranosyl-cytosine (CNDAC): design of a potential mechanism-based DNA-strand-breaking antineoplastic nucleoside J. Med. Chem. 34 1991 2917 2919 (http://www.ncbi.nlm.nih.gov/pubmed/1895307 (accessed January 20, 2015))
122. A.L. Klibanov, K. Maruyama, V.P. Torchilin, and L. Huang Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes FEBS Lett. 268 1990 235 237 (http://www.ncbi.nlm.nih.gov/pubmed/2384160 (accessed April 29, 2015))
123. H. Otsuka, Y. Nagasaki, and K. Kataoka PEGylated nanoparticles for biological and pharmaceutical applications Adv. Drug Deliv. Rev. 55 2003 403 419 (http://www.ncbi.nlm.nih.gov/pubmed/12628324 (accessed April 29, 2015))
124. F. Bai, C. Wang, Q. Lu, M. Zhao, F.-Q. Ban, and D.-H. Yu Nanoparticle-mediated drug delivery to tumor neovasculature to combat P-gp expressing multidrug resistant cancer Biomaterials 34 2013 6163 6174 10.1016/j.biomaterials.2013.04.062
125. M. Argov, T. Bod, S. Batra, and R. Margalit Novel steroid carbamates reverse multidrug-resistance in cancer therapy and show linkage among efficacy, loci of drug action and P-glycoprotein's cellular localization Eur. J. Pharm. Sci. 41 2010 53 59 10.1016/j.ejps.2010.05.012
126. J.M. Koziara, T.R. Whisman, M.T. Tseng, and R.J. Mumper In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors J. Control. Release 112 2006 312 319 10.1016/j.jconrel.2006.03.001
127. L. Hetian, A. Ping, S. Shumei, L. Xiaoying, H. Luowen, and W. Jian A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor J. Biol. Chem. 277 2002 43137 43142 10.1074/jbc.M203103200
128. T. Donnem, J. Hu, M. Ferguson, O. Adighibe, C. Snell, and A.L. Harris Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment? Cancer Med. 2 2013 427 436 10.1002/cam4.105
129. A.L. Harris Hypoxia - a key regulatory factor in tumour growth Nat. Rev. Cancer 2 2002 38 47 10.1038/nrc704
130. R.G. Bristow, and R.P. Hill Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability Nat. Rev. Cancer 8 2008 180 192 10.1038/nrc2344
131. D.M. Gilkes, G.L. Semenza, and D. Wirtz Hypoxia and the extracellular matrix: drivers of tumour metastasis Nat. Rev. Cancer 14 2014 430 439 10.1038/nrc3726
132. H.-J. Eom, J.-M. Ahn, Y. Kim, and J. Choi Hypoxia inducible factor-1 (HIF-1)-flavin containing monooxygenase-2 (FMO-2) signaling acts in silver nanoparticles and silver ion toxicity in the nematode, Caenorhabditis Toxicol. Appl. Pharmacol. 270 2013 106 113 10.1016/j.taap.2013.03.028
133. X.-Q. Liu, M.-H. Xiong, X.-T. Shu, R.-Z. Tang, and J. Wang Therapeutic delivery of siRNA silencing HIF-1 alpha with micellar nanoparticles inhibits hypoxic tumor growth Mol. Pharm. 9 2012 2863 2874 10.1021/mp300193f
134. M. Prat, I. Morra, G. Bussolati, and P.M. Comoglio CAR-3, a monoclonal antibody-defined antigen expressed on human carcinomas Cancer Res. 45 1985 5799 5807 (http://www.ncbi.nlm.nih.gov/pubmed/2413998 (accessed January 21, 2015))
135. M. Prat, B. Griselli, A. Bernardi, P. Rossino, G.L. Candelaresi, and A.P. Cappa Expression of the monoclonal antibody-defined CAR-3 epitope on neoplastic and preneoplastic lesions of the colon mucosa Eur. J. Cancer Clin. Oncol. 23 1987 923 932 (http://www.ncbi.nlm.nih.gov/pubmed/2444440 (accessed January 30, 2015))
136. P. Crosasso, P. Brusa, F. Dosio, S. Arpicco, D. Pacchioni, and F. Schuber Antitumoral activity of liposomes and immunoliposomes containing 5-fluorouridine prodrugs J. Pharm. Sci. 86 1997 832 839 10.1021/js9604467
137. M. Prat, E. Medico, P. Rossino, C. Garrino, and P.M. Comoglio Biochemical and immunological properties of the human carcinoma-associated CAR-3 epitope defined by the monoclonal antibody AR-3 Cancer Res. 49 1989 1415 1421 (http://www.ncbi.nlm.nih.gov/pubmed/2466553 (accessed January 21, 2015))
138. S. Hosokawa, T. Tagawa, H. Niki, Y. Hirakawa, K. Nohga, and K. Nagaike Efficacy of immunoliposomes on cancer models in a cell-surface-antigen-density-dependent manner Br. J. Cancer 89 2003 1545 1551 10.1038/sj.bjc.6601341
139. C. Chapman, A. Murray, J. Chakrabarti, A. Thorpe, C. Woolston, and U. Sahin Autoantibodies in breast cancer: their use as an aid to early diagnosis Ann. Oncol. 18 2007 868 873 10.1093/annonc/mdm007
140. L.G. Durrant, V.S. Byers, P.J. Scannon, R. Rodvien, K. Grant, and R.A. Robins Humoral immune responses to XMMCO-791-RTA immunotoxin in colorectal cancer patients Clin. Exp. Immunol. 75 1989 258 264 (http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1542124&tool=pmcentrez&rendertype=abstract, accessed January 21, 2015)
141. T. Hamaguchi, Y. Matsumura, Y. Nakanishi, K. Muro, Y. Yamada, and Y. Shimada Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts Cancer Sci. 95 2004 608 613 (http://www.ncbi.nlm.nih.gov/pubmed/15245599)
142. C.M. Lee, T. Tanaka, and T. Murai Novel Chondroitin Sulfate-binding Cationic Liposomes Loaded with Cisplatin Efficiently Suppress the Local Growth and Liver Metastasis of Tumor Cells in Vivo Cancer Res. 62 2002 4282 4288
143. S.H. Jalalian, S.M. Taghdisi, N. Shahidi Hamedani, S.A.M. Kalat, P. Lavaee, and M. Zandkarimi Epirubicin loaded super paramagnetic iron oxide nanoparticle-aptamer bioconjugate for combined colon cancer therapy and imaging in vivo Eur. J. Pharm. Sci. 50 2013 191 197 10.1016/j.ejps.2013.06.015
144. J. Liao, B. Liu, J. Liu, J. Zhang, K. Chen, and H. Liu Cell-specific aptamers and their conjugation with nanomaterials for targeted drug delivery Expert Opin. Drug Deliv. 2014 1 14 10.1517/17425247.2015.966681
145. J.W. Lee, H.J. Kim, and K. Heo Therapeutic aptamers: Developmental potential as anticancer drugs BMB Rep. 48 2015 234 237
146. C.A. Reis, H. Osorio, L. Silva, C. Gomes, and L. David Alterations in glycosylation as biomarkers for cancer detection J. Clin. Pathol. 63 2010 322 329 10.1136/jcp.2009.071035
147. S. Pinho, N.T. Marcos, B. Ferreira, A.S. Carvalho, M.J. Oliveira, and F. Santos-Silva Biological significance of cancer-associated sialyl-Tn antigen: modulation of malignant phenotype in gastric carcinoma cells Cancer Lett. 249 2007 157 170 10.1016/j.canlet.2006.08.010
148. S. Wang, X. Chen, and M. Tang Quantitative assessment of the diagnostic role of MUC1 in pancreatic ductal adenocarcinoma Tumour Biol. 35 2014 9101 9109 10.1007/s13277-014-2186-4
149. E. Saeland, A.I. Belo, S. Mongera, I. van Die, G.A. Meijer, and Y. van Kooyk Differential glycosylation of MUC1 and CEACAM5 between normal mucosa and tumour tissue of colon cancer patients Int. J. Cancer 131 2012 117 128 10.1002/ijc.26354
150. Y. Tamura, M. Higashi, S. Kitamoto, S. Yokoyama, M. Osako, and M. Horinouchi MUC4 and MUC1 expression in adenocarcinoma of the stomach correlates with vessel invasion and lymph node metastasis: an immunohistochemical study of early gastric cancer PLoS One 7 2012 e49251 10.1371/journal.pone.0049251
151. A.L. Sørensen, C.A. Reis, M.A. Tarp, U. Mandel, K. Ramachandran, and V. Sankaranarayanan Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance Glycobiology 16 2006 96 107 10.1093/glycob/cwj044
152. H. Inuma, K. Maruyama, K. Okinaga, K.A. Sasaki, T. Sekine, and O. Ishida Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer Int. J. Cancer 137 2002 130 137 10.1002/ijc.10242
153. O. Ishida, K. Maruyama, H. Tanahashi, M. Iwatsuru, K. Sasaki, and M. Eriguchi Liposomes Bearing Polyethyleneglycol-Coupled Transferrin with Intracellular Targeting Property to the Solid Tumors In Vivo Pharm. Res. 18 2001 1042 1048
154. M. Ohkuma, N. Haraguchi, H. Ishii, K. Mimori, F. Tanaka, and H.M. Kim Absence of CD71 transferrin receptor characterizes human gastric adenosquamous carcinoma stem cells Ann. Surg. Oncol. 19 2012 1357 1364 10.1245/s10434-011-1739-7
155. E.R. Camp, C. Wang, E.C. Little, P.M. Watson, K.F. Pirollo, and A. Rait Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy Cancer Gene Ther. 20 2013 222 228 10.1038/cgt.2013.9
156. M. Cinci, S. Mamidi, W. Li, V. Fehring, and M. Kirschfink Targeted delivery of siRNA using transferrin-coupled lipoplexes specifically sensitizes CD71 high expressing malignant cells to antibody-mediated complement attack Target. Oncol. 2014 10.1007/s11523-014-0345-6
157. S. Tortorella, and T.C. Karagiannis Transferrin receptor-mediated endocytosis: a useful target for cancer therapy J. Membr. Biol. 247 2014 291 307 10.1007/s00232-014-9637-0
158. N. Akita, F. Maruta, L.W. Seymour, D.J. Kerr, A.L. Parker, and T. Asai Identification of oligopeptides binding to peritoneal tumors of gastric cancer Cancer Sci. 97 2006 1075 1081 10.1111/j.1349-7006.2006.00291.x
159. C.-H. Chen, D.-Z. Liu, H.-W. Fang, H.-J. Liang, T.-S. Yang, and S.-Y. Lin Evaluation of multi-target and single-target liposomal drugs for the treatment of gastric cancer Biosci. Biotechnol. Biochem. 72 2014 1586 1594 10.1271/bbb.80096
160. A. Basit, J. Wang, V. Yadav, A. Smart, and S. Tajiri Towards oral delivery of biopharmaceuticals: an assessment of the gastrointestinal stability of 17 peptide drugs Mol. Pharm. 2015 10.1021/mp500809f
161. H. Wang, N. Zhou, R. Zhang, Y. Wu, R. Zhang, and S. Zhang Identification and localization of gastrointestinal hormones in the skin of the bullfrog Rana catesbeiana during periods of activity and hibernation Acta Histochem. 116 2014 1418 1426 10.1016/j.acthis.2014.09.005
162. A. Stengel, M. Goebel-Stengel, L. Wang, M. Larauche, J. Rivier, and Y. Taché Central somatostatin receptor 1 activation reverses acute stress-related alterations of gastric and colonic motor function in mice Neurogastroenterol. Motil. 23 2011 e223 e236 10.1111/j.1365-2982.2011.01706.x
163. L. Sun, and D.H. Coy Somatostatin and its Analogs Curr. Drug Targets 2014 (http://www.ncbi.nlm.nih.gov/pubmed/25483222, accessed January 26, 2015) (ahead of print)
164. A. Giustina, G. Mazziotti, F. Maffezzoni, V. Amoroso, and A. Berruti Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors Expert Opin. Investig. Drugs 23 2014 1619 1635 10.1517/13543784.2014.942728
165. A. Corti, F. Pastorino, F. Curnis, W. Arap, M. Ponzoni, and R. Pasqualini Targeted drug delivery and penetration into solid tumors Med. Res. Rev. 32 2012 1078 1091 10.1002/med.20238
166. C. Hu, C. Yi, Z. Hao, S. Cao, H. Li, and X. Shao The effect of somatostatin and SSTR3 on proliferation and apoptosis of gastric cancer cells Cancer Biol. Ther. 3 2014 726 730 10.4161/cbt.3.8.962
167. Y. Dong, S.L. Morris-Natschke, and K.-H. Lee Biosynthesis, total syntheses, and antitumor activity of tanshinones and their analogs as potential therapeutic agents Nat. Prod. Rep. 28 2011 529 542 10.1039/c0np00035c
168. L. Wang, J.H.K. Yeung, T. Hu, W.Y. Lee, L. Lu, and L. Zhang Dihydrotanshinone induces p53-independent but ROS-dependent apoptosis in colon cancer cells Life Sci. 93 2013 344 351 10.1016/j.lfs.2013.07.007
169. D.-S. Lee, S.-H. Lee, G.-S. Kwon, H.-K. Lee, J.-H. Woo, and J.-G. Kim Inhibition of DNA topoisomerase I by dihydrotanshinone I, components of a medicinal herb Salvia miltiorrhiza Bunge Biosci. Biotechnol. Biochem. 63 2014 1370 1373 10.1271/bbb.63.1370
170. F. Zare Shahneh, S. Valiyari, B. Baradaran, J. Abdolalizadeh, A. Bandehagh, and A. Azadmehr Inhibitory and cytotoxic activities of salvia officinalis L. Extract on human lymphoma and leukemia cells by induction of apoptosis Adv. Pharm. Bull. 3 2013 51 55 10.5681/apb.2013.009
171. D. Goren, A.T. Horowitz, S. Zalipsky, M.C. Woodle, Y. Yarden, and A. Gabizon Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies Br. J. Cancer 74 1996 1749 1756 (http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2077226&tool=pmcentrez&rendertype=abstract)
172. I. Uyama, K. Kumai, and T. Yasuda Therapeutic effect by using Fab′ fragment in the treatment of carcinoembryonic antigen-positive human solid tumors with adriamycinentrapped immunoliposomes Jpn. J. Cancer Res 85 1994 434 440 (http://onlinelibrary.wiley.com/doi/10.1111/j.1349-7006.1994.tb02377.x/full, accessed July 5, 2014)
173. Z. Sun, and N. Zhang Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy World J. Surg. Oncol. 12 2014 397 10.1186/1477-7819-12-397
174. E.-C. Lee, J.-Y. Yang, K.-G. Lee, S.-Y. Oh, Y.-S. Suh, and S.-H. Kong The value of postoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the early detection of gastric cancer recurrence after curative resection J. Gastric Cancer 14 2014 221 228 10.5230/jgc.2014.14.4.221
175. P. Sapra, E.H. Moase, J. Ma, and T.M. Allen Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab′ fragments Clin. Cancer Res. 10 2004 1100 1111
176. Y. Matsumura Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer Ann. Oncol. 15 2004 517 525 10.1093/annonc/mdh092
177. P. Michl, and T.M. Gress Current concepts and novel targets in advanced pancreatic cancer Gut 62 2013 317 326 10.1136/gutjnl-2012-303588
178. J.M. Winter, J.L. Cameron, K.A. Campbell, M.A. Arnold, D.C. Chang, and J. Coleman 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience J. Gastrointest. Surg. 10 2006 1199 1210 10.1016/j.gassur.2006.08.018 (discussion 1210-1)
179. Amican Cancer Society Cancer Facts & Figures 2012 Am. Cancer Soc. Atlanta GA, USA 25 26
180. K.P. Olive, M.A. Jacobetz, C.J. Davidson, A. Gopinathan, D. McIntyre, and D. Honess Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer Science 324 2009 1457 1461 10.1126/science.1171362
181. E. Murphy, and B. Majeti Targeted nanogels: a versatile platform for drug delivery to tumors Mol. Cancer 10 2011 972 982 10.1158/1535-7163.MCT-10-0729.Targeted
182. T.R. Daniels, E. Bernabeu, J.A. Rodríguez, S. Patel, M. Kozman, and D.A. Chiappetta The transferrin receptor and the targeted delivery of therapeutic agents against cancer Biochim. Biophys. Acta 1820 2012 291 317 10.1016/j.bbagen.2011.07.016
183. T.R. Daniels, T. Delgado, G. Helguera, and M.L. Penichet The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells Clin. Immunol. 121 2006 159 176 10.1016/j.clim.2006.06.006
184. T.R. Daniels, T. Delgado, J.A. Rodriguez, G. Helguera, and M.L. Penichet The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer Clin. Immunol. 121 2006 144 158 10.1016/j.clim.2006.06.010
185. L. Xu, C.-C. Huang, W. Huang, W.-H. Tang, A. Rait, and Y.Z. Yin Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes Mol. Cancer Ther. 1 2002 337 346 (http://www.ncbi.nlm.nih.gov/pubmed/12489850 (accessed January 28, 2015))
186. N. Senzer, J. Nemunaitis, D. Nemunaitis, C. Bedell, G. Edelman, and M. Barve Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors Mol. Ther. 21 2013 1096 1103 10.1038/mt.2013.32
187. C. Qian, Y. Wang, Y. Chen, L. Zeng, Q. Zhang, and X. Shuai Suppression of pancreatic tumor growth by targeted arsenic delivery with anti-CD44v6 single chain antibody conjugated nanoparticles Biomaterials 34 2013 6175 6184 10.1016/j.biomaterials.2013.04.056
188. S.L. Soignet, P. Maslak, Z.G. Wang, S. Jhanwar, E. Calleja, and L.J. Dardashti Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide N. Engl. J. Med. 339 1998 1341 1348 10.1056/NEJM199811053391901
189. W. Wang, M. Adachi, R. Zhang, J. Zhou, and D. Zhu A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells Pancreas 38 2009 e114 e123 10.1097/MPA.0b013e3181a0b6f2
190. H. Maeda, S. Hori, H. Nishitoh, H. Ichijo, O. Ogawa, and Y. Kakehi Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer Cancer Res. 61 2001 5432 5440 (http://www.ncbi.nlm.nih.gov/pubmed/11454688 (accessed January 28, 2015))
191. K. Mima, H. Okabe, T. Ishimoto, H. Hayashi, S. Nakagawa, and H. Kuroki The expression levels of CD44v6 are correlated with the invasiveness of hepatocellular carcinoma in vitro, but do not appear to be clinically significant Oncol. Lett. 3 2012 1047 1051 10.3892/ol.2012.611
192. D. Coppola, M. Hyacinthe, L. Fu, A.B. Cantor, R. Karl, and J. Marcet CD44V6 expression in human colorectal carcinoma Hum. Pathol. 29 1998 627 635 (http://www.ncbi.nlm.nih.gov/pubmed/9635685 (accessed January 28, 2015))
193. A. Yamaguchi, T. Goi, J. Yu, Y. Hirono, M. Ishida, and A. Iida Expression of CD44v6 in advanced gastric cancer and its relationship to hematogenous metastasis and long-term prognosis J. Surg. Oncol. 79 2002 230 235 10.1002/jso.10082
194. S. Saito, H. Okabe, M. Watanabe, T. Ishimoto, M. Iwatsuki, and Y. Baba CD44v6 expression is related to mesenchymal phenotype and poor prognosis in patients with colorectal cancer Oncol. Rep. 29 2013 1570 1578 10.3892/or.2013.2273
195. J. Kuncová, Z. Kostrouch, M. Viale, R. Revoltella, and V. Mandys Expression of CD44v6 correlates with cell proliferation and cellular atypia in urothelial carcinoma cell lines 5637 and HT1197 Folia Biol. (Praha) 51 2005 3 11 (http://www.ncbi.nlm.nih.gov/pubmed/15783086, accessed January 28, 2015)
196. Y. Chen, K. Huang, X. Li, X. Lin, Z. Zhu, and Y. Wu Generation of a stable anti-human CD44v6 scFv and analysis of its cancer-targeting ability in vitro Cancer Immunol. Immunother. 59 2010 933 942 10.1007/s00262-010-0819-z
197. X. Peng, Y. Wang, and D. Huang Targeted delivery of cisplatin to lung cancer using ScFvEGFR-heparin-cisplatin nanoparticles ACS Nano 5 2011 9480 9493 10.1021/nn202410f.Targeted
198. L. Yang, H. Mao, Y.A. Wang, Z. Cao, X. Peng, and X. Wang Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging Small 5 2009 235 243 10.1002/smll.200800714
199. A.P. Chapman PEGylated antibodies and antibody fragments for improved therapy: a review Adv. Drug Deliv. Rev. 54 2002 531 545 10.1016/S0169-409X(02)00026-1
200. Y. Yang, Y. Yang, X. Xie, X. Cai, H. Zhang, and W. Gong PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptide-doxorubicin conjugate for tumor-specific therapy Biomaterials 35 2014 4368 4381 10.1016/j.biomaterials.2014.01.076
201. D.B. Kirpotin, D.C. Drummond, Y. Shao, M.R. Shalaby, K. Hong, and U.B. Nielsen Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models Cancer Res. 66 2006 6732 6740 10.1158/0008-5472.CAN-05-4199
202. D.W. Bartlett, H. Su, I.J. Hildebrandt, W.A. Weber, and M.E. Davis Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging Proc. Natl. Acad. Sci. U. S. A. 104 2007 15549 15554 10.1073/pnas.0707461104
203. A.M. Wu, P.J. Yazaki, S.W. Tsai, K. Nguyen, A.L. Anderson, and D.W. McCarthy High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment Proc. Natl. Acad. Sci. U. S. A. 97 2000 8495 8500 10.1073/pnas.150228297
204. G. Sundaresan, P.J. Yazaki, J.E. Shively, R.D. Finn, S.M. Larson, and A.A. Raubitschek 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice J. Nucl. Med. 44 2003 1962 1969 (http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4167879&tool=pmcentrez&rendertype=abstract, accessed November 20, 2014)
205. C. Mamot, D.C. Drummond, C.O. Noble, V. Kallab, Z. Guo, and K. Hong Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo Cancer Res. 65 2005 11631 11638 10.1158/0008-5472.CAN-05-1093
206. S. Hussain, A. Plückthun, T.M. Allen, and U. Zangemeister-Wittke Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system Mol. Cancer Ther. 6 2007 3019 3027 10.1158/1535-7163.MCT-07-0615
207. P. Vlieghe, V. Lisowski, J. Martinez, and M. Khrestchatisky Synthetic therapeutic peptides: science and market Drug Discov. Today 15 2010 40 56 10.1016/j.drudis.2009.10.009
208. S. Hosokawa, T. Tagawa, H. Niki, Y. Hirakawa, N. Ito, and K. Nohga Establishment and evaluation of cancer-specific human monoclonal antibody GAH for targeting chemotherapy using immunoliposomes Hybrid. Hybridomics 23 2004 109 120 10.1089/153685904774129711
209. Study of MBP-426 in patients with second line gastric, gastroesophageal, or esophageal adenocarcinoma - full text view - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00964080 (accessed February 18, 2015)
210. M. Kinoshita, Y. Mitsui, N. Kakoi, K. Yamada, T. Hayakawa, and K. Kakehi Common glycoproteins expressing polylactosamine-type glycans on matched patient primary and metastatic melanoma cells show different glycan profiles J. Proteome Res. 13 2014 1021 1033 10.1021/pr401015b
211. Safety study of CALAA-01 to treat solid tumor cancers - full text view - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00689065?term=NCT00689065&rank=1 (accessed February 18, 2015)
212. Safety study of infusion of SGT-53 to treat solid tumors - full text view - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00470613?term=NCT00470613&rank=1 (accessed February 18, 2015)
213. J. Baselga, D. Pfister, M.R. Cooper, R. Cohen, B. Burtness, and M. Bos Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin J. Clin. Oncol. 18 2000 904 914 (http://www.ncbi.nlm.nih.gov/pubmed/10673534 (accessed February 18, 2015))
214. J.D. Heidel, J.Y.-C. Liu, Y. Yen, B. Zhou, B.S.E. Heale, and J.J. Rossi Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo Clin. Cancer Res. 13 2007 2207 2215 10.1158/1078-0432.CCR-06-2218
215. F. Pastorino, C. Brignole, M. Loi, D. Di Paolo, A. Di Fiore, and P. Perri Nanocarrier-mediated targeting of tumor and tumor vascular cells improves uptake and penetration of drugs into neuroblastoma Front. Oncol. 3 2013 190 10.3389/fonc.2013.00190
216. I. Fichtner, W. Slisow, J. Gill, M. Becker, B. Elbe, and T. Hillebrand Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas Eur. J. Cancer 40 2004 298 307 10.1016/j.ejca.2003.10.011
217. J.J. Tentler, A.C. Tan, C.D. Weekes, A. Jimeno, S. Leong, and T.M. Pitts Patient-derived tumour xenografts as models for oncology drug development Nat. Rev. Clin. Oncol. 9 2012 338 350 10.1038/nrclinonc.2012.61
218. D. Abate-Daga, K.H. Lagisetty, E. Tran, Z. Zheng, L. Gattinoni, and Z. Yu A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer Hum. Gene Ther. 25 2014 1003 1012 10.1089/hum.2013.209
219. B. Rubio-Viqueira, and M. Hidalgo Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients Clin. Pharmacol. Ther. 85 2009 217 221 10.1038/clpt.2008.200